Follicular Lymphoma | Tumor

FDA Speeds Up Review of CAR-T Cell Therapy to Treat Follicular Lymphoma

October 28th 2021, 7:00pm

Article

Kymriah was granted a priority review for the treatment of pretreated patients with relapsed or refractory follicular lymphoma.

When the Daughter of a Pediatric Oncologist Receives a Cancer Diagnosis

October 14th 2021, 3:00pm

Podcast

“We tried very hard, my daughter and I, to have a daughter-father relationship, not a daughter-doctor relationship,” said Dr. Michael Weiner on this episode of the “CURE® Talks Cancer” podcast, in which he discussed his career, his own cancer journey and his daughter’s diagnosis.

FDA Approves Yescarta for Third-Line Treatment of Relapsed or Refractory Follicular Lymphoma

March 6th 2021, 2:06am

Article

This accelerated FDA approval is the first CAR T-cell therapy approved for the treatment of patients with indolent follicular lymphoma.

Bringing Clinical Trials in Cancer Closer to Home

February 17th 2021, 8:00pm

Article

Local access to national cancer studies allows patients to receive promising new treatments in the most convenient setting possible: Their own community.

FDA Approves Ukoniq in Certain Previously Treated Patients with Marginal Zone and Follicular Lymphoma

February 5th 2021, 8:57pm

Article

The Food and Drug Administration has granted an accelerated approval to Ukoniq for the treatment of certain adults with previously treated relapsed or refractory marginal zone lymphoma and relapsed or refractory follicular lymphoma.

The Top 5 News and Updates in Follicular Lymphoma That Patients May Have Missed in 2020

December 30th 2020, 10:00pm

Article

A roundup of some of the most read news and updates in follicular lymphoma in 2020 from CURE®.

One-Half Teaspoon

December 26th 2020, 7:00pm

Article

Aileen Holthaus writes about her first day of chemotherapy for follicular lymphoma, and the challenges it presented.

Novel Drugs Look Promising in the Treatment of Follicular Lymphoma

November 4th 2020, 4:00pm

Article

One recently approved drug and two experimental treatments offer the promise of a wider range of options for patients with follicular lymphoma, according to Dr. Germame Ajebo.

Trading Places: A Father and Daughter's Journey with Lymphoma

October 30th 2020, 6:00pm

Article

Bob Meyers and his daughter Leslie Watson have always been close. In fact, they live right down the street from one another in their Georgia neighborhood. So, when Watson received the diagnosis of clear cell carcinoma in the summer of 1996, and then follicular lymphoma later that fall, Meyers was there by her side as her devoted caregiver.

Tazverik a Safe and Effective Option for Heavily Pretreated Patients with Follicular Lymphoma

October 27th 2020, 9:00pm

Article

In addition to showing clinically meaningful, durable responses, Tazverik (tazemetostat) was generally well-tolerated in heavily pretreated patients with relapsed or refractory follicular lymphoma, according to the results of an open-label, single-arm, multicenter phase 2 study.